Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells

By Lubna Patrawala, Tammy Calhoun, Robin Schneider‐Broussard, Hangwen Li, Bobby Bhatia, Shaohua Tang, J. Reilly, D. Chandra, J. Zhou, K. Claypool and 2 more. Oncogene, 2006

941 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c3ac215f96da8024aa1595cbe586e31c4f86c3f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

In Oncology

Citations in the corpus

Molecular genetics of prostate cancer: new prospects for old challenges. (2010, methodology): “In human prostate cancer, CD44 has been used as a marker to enrich for TICs from established xenografts (Patrawala et al. 2006), while further enrichment of TICs was obtained in a subsequent study by sorting for a2b1 integrin CD44 cells (Patrawala et al.”
Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “…of the “cell of origin” remains an area of active research for both hematological malignancies (Passegue et al. 2003) and solid tumors (Al-Hajj et al. 2003; Singh et al. 2004; Sanai et al. 2005; Taylor et al. 2005; Patrawala et al. 2006; Li et al. 2007; O’Brien et al. 2007; Prince et al. 2007).”
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. (2009, background): “CD44 has been used to enrich for putative cancer stem cells in other types of solid cancer, such as breast, head and neck, and pancreas and prostate (Al-Hajj et al., 2003; Patrawala et al., 2006; Li et al., 2007; Prince et al., 2007).”
Evolution of the cancer stem cell model. (2014, background): “…including brain (Singh et al., 2004), head and neck (Prince et al., 2007), pancreas (Hermann et al., 2007; Li et al., 2007), lung (Eramo et al., 2008), prostate (Collins et al., 2005; Patrawala et al., 2006), colon (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), and sarcoma (Wu et al., 2007).”
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway (2008, background): “To date, the existence of CSCs has been proven in the context of many cancers, including those of leukemia, breast cancer, glioblastoma, prostate cancer, pancreatic cancer and colon cancer (Lapidot et al., 1994; Bonnet and Dick, 1997; Al-Hajj et al., 2003; Hemmati et al., 2003; Singh et al., 2003, 2”
Cancer stem cells: models and concepts. (2007, background): “In addition to breast and brain tumors, interesting results are being accumulated on prostate cancer, where progenitor/ tumorigenic subpopulations appear characterized by the expression of CD44 (64, 65).”
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. (2008, background): “appearance by visual observation and palpation, and tumor latencies (23)”
Identification and expansion of the tumorigenic lung cancer stem cell population (2008, background): “Several solid tumors contain CD133þ tumorigenic cancer stem cells, including glioblastoma, medulloblastoma and prostate carcinomas.(7,8,11) Therefore, we first evaluated whether CD133þ cancer cells could be found within lung tumors.”